Member Info for Saintsmith

Hi , sorry k , was going to private message you on twitter . I’m not a weirdo I promise ;) married with bulldogs . Share talk news , that’s all .

Hi k , are your messages blocked on twitter .

@ troublesome . A VALaciraptor.

In regards to bethalls leaving tweet .

Thanks to Tilly for infectious energy( rocket emoji )
?
WTF ?
Tilly whizz , aim super ramper ?????

Well , today went as expected to be honest .

This has indeed been a tough hold this last six months .

Aim is based on sentiment and on low volume trading days like today the share price can drift 5% either way.

The “Botty Boys “ have been out in force today which says it all really . It’s a buy !

U.K. Travel testing isn’t Novacyt bread and butter . It never has been .

PCR is going nowhere , yourgene has recently been awarded a £34 million contract for their in house PCR testing .
We have ex big pharma staff jumping ship to join our company .
These guys are intelligent , top calibre recruits and will have done plenty of research into NCYT before leaving very well paid jobs to start a fresh .

We are not just a covid stock , we have over 500 diagnostic tests at market .

The world is waking up to how important POC diagnostics are , covid has sped up this .
The company have done a fantastic job of keeping up to variant detection and suitable tests but have been dry bummed by an over ordering , unknowledgeable , untrustworthy and panic stricken DHSC .

The board have not done enough to calm investors nerves or sell or promote the company either .
Hopefully DA will rectify this .

There will be some of the old guard on here , myself included who are kicking them selves for not selling at £12 .
If I did all my profits would be re invested into this fantastic company .

Your bang on the money there troublesome .
Putting up NI to pay for social care although if they carry on not protecting the old folks homes and keeping the elderly and vulnerable safely protected with accurate testing there may not be many of them left .
I’m sure the government would hate that , wouldn’t they ??

I think you are right RBM they are talking about ending PCR tests on returnees to the U.K. from most world wide destinations if you are double jabbed .
Luckily we are involved in genomic sequencing which can only be done via PCR and we have LFT coming to market soon . We also have worldwide sales to fall back on .
So hopefully protected in the long term but I expect more volatility .
This decision by the government will come back to haunt them .
Been double jabbed does not stop the spread and many double jabbed are dying .
It is all about control and making things harder for the unjabbed.
At least after having a PCR before returning from ****stan , turkey etc you know 100% that you are free from covid .
Upon dropping these tests and if the government carry on using in accurate LFT they will be unleashing covid on this island yet again and many will suffer .

Oxford nanopore . Value £3.4 billion .
AIMING TO BREAK EVEN IN FIVE YEARS !
FFS
Our time will come . Hold tight .

That list of FDA non approved test removal is very interesting .

There are some tests from big pharma in there with tests removed , Siemens healthcare , beckman coulter and even some from thermo fischer .

Come on big boys make us an offer for a company with the original gold standard FDA and WHO approved arsenal of covid tests .
Starting bid £15 per share ;)

The bbc and the media are on a mission against PCR at the moment Wilson .
Plenty of rogue PCR testing companies not delivering on time . Randox been one of them .
Weekly bioinformatics schedules should be mandatory as we do with our tests .
Regulation will be tightened and as all the rogue traders shut up shop it will send more tests our way .
It’s all about variant control and genomic sequencing now and this can only be done with PCR testing .
Novacyt will do very well out of this .
Sharon pea**** head of COG U.K. is well aware of Novacyt as she has featured on our webinars .

Wise words misteretrader.

Come on guys and girls we are making around £ ten million a month .
Covid isn’t going anywhere .
Winter is coming.

Look at all the bloody job vacancies !

Look at all the ex big pharma staff leaving well established companies to come and work for Novacyt .

How many more clues do you need ???????

Talking of keeping up with manufacturing demands .

Any speculations to who our OEM is for the upcoming lateral flow test ?

Vote YES
Vote LAST MINUTE
Make them sweat .

The way I see it regarding voting “no” early is you might be cutting off your nose to spite your face
.
We are nearly at the end of the third quarter and are still waiting on our LFT releases.

Personally I will hold fire until the night before deadline to see what yet might come.

If they need enough votes to pass any motions who knows what little nuggets they might tempt us with .
I feel the board needs to sweat just a little .

Yvette Cooper talking on world at one on radio 4 .
Explaining how important PCR tests are in genomic sequencing and keeping variants in check .
Despite sajids talks on PCR been unnecessary on return from holiday PCR will not be going anywhere .
You need to have genomic surveillance on variants to know that the vaccines you are using are effective against the dominant strain of covid .

The mail have always had an axe to grind against PCR , They probably have connections with innova .
However it was backed up by sajid javid on sky news this morning .

Hasn’t nanopores dna nudge POC they earth shattering run rate of one test in 90 minutes ?
There will be many bigger players than NCYT that would only dream of owning the rights of our Q16 and Q32.

Interesting write up regarding Oxford nanopore and illumina in the guardian .
I still can believe Oxford nanopore are valued at £2.4 billion .
We are so undervalued !

“
Oxford Nanopore, the DNA sequencing and analytics spin-out from Oxford University, is the current “hot” company in UK biotech circles. The pandemic, runs the thinking, hasn’t just delivered a big advance in revenues from Covid-related contracts, but has also transformed horizons in the business of “analysis of any living thing”.

Advertisement

So there will be relief among sensitive UK politicians that Nanopore is sticking to plans to go public in London rather than New York. “It’s an urban myth that you can do much better on Nasdaq,” says chief executive Gordon Sanghera. That’s the sprit.

But there is a US-style feature to the float that, potentially, could cause traditional UK shareholders to splutter. It’s the “limited anti-takeover” share, to be held by Sanghera, that carries the right to refuse an unwanted takeover bid for a period of three years.

A governance abomination? Strictly speaking, yes: equal rights for equal economic risk remains an excellent principle. But, equally, a one-size-fits-all approach feels too rigid. The case for exceptionalism for Nanopore is that one genuinely wants to see the company have a shot at converting its intellectual patents into commercial success.

By way of example of what’s possible in this field, look at US gene-sequencing company Illumina, which back in 2012 fended off a $6.8bn (£4.9bn) bid from the giant Roche. Nine years later, Illumina’s value has risen tenfold. There is no guarantee, of course, that Nanopore, valued at £2.4bn in its last private funding round, will be able to achieve anything comparable. But, in the interest of the broader UK biotech industry, one would like to see it have a go.

The three-year “sunset” clause applies to the anti-takeover shares, which is a critical feature: the control-freakery won’t last for ever. The structure means Nanopore can’t currently have a so-called “premium” market listing, but is within the spirit of Lord Hill’s recent review of the listing regime. We should probably relax.

I’m pretty sure NPH testing@lba is done by yourgene Wilson .